PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients

Mugosa, Snezana; Djordjević, Nataša; Bukumirić, Zoran; Djukanović, Nina; Cukic, Jelena; Radosavljevic, Ivan; Baskić, Dejan; Protić, Dragana; Zdravković, Marija; Todorović, Zoran

doi:10.1111/1440-1681.12531

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tel: +420 495067295; Fax: +420 495067170; E-mail: mladenkap@faf.cuni.cz ment with both types of substances is problematic: in around 5-45% of ASA users there is a treatment failure and/or resistance [1] and antagonists to ADP receptors (ticlopidin and clopidogrel) are associated with drug interactions [2,3]. The latest representatives of the latter (ticagrelor, elinogrel, cangrelor) are not prodrugs and hence have a smaller potential for such interactions but their use in clinical practise is relatively recent and the side-effects of long-term treatment have not yet been established.…”

Section: Introductionmentioning

confidence: 99%

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a Potentially Novel Antiplatelet Drug which Antagonizes the Effect of Thromboxane A2

Applová

Veljović

Muratović

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a Potentially Novel Antiplatelet Drug which Antagonizes the Effect of Thromboxane A2

Applová

Veljović

Muratović

et al. 2018

View full text Add to dashboard Cite

show abstract

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives

Djordjević

2022

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Mugosa

Todorović

Cukic³

et al. 2021

Open Life Sciences

View full text Add to dashboard Cite

Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene. Thus, the aim of this study was to investigate the effect of ABCB1 genetic polymorphism on clopidogrel efficacy and safety and to determine the frequency distribution of its most common single nucleotide polymorphisms (SNPs) in 106 Montenegrin cardiology patients. Clopidogrel efficacy and safety were followed up during 1 year after hospitalization, with the lack of efficacy and adverse drug reactions observed in 11 (10.4%) and 8 patients (7.5%), respectively. Genotyping for ABCB1 SNPs rs1128503 (1236C > T), rs2032582 (2677G > A/T), and rs1045642 (3435C > T) was performed by the real-time PCR method, and the variant alleles were detected with the frequencies of 42.9, 44.8, and 52.8%, respectively. No significant association was observed between any of the examined genotypes and clopidogrel efficacy (p = 0.253) or safety (p = 0.424). Due to small sample size, co-treatment with other drugs, and other genetic factors not taken into account, we believe the absence of correlation between ABCB1 genotypes and indicators of clopidogrel efficacy and safety in this study should be apprehended conditionally, and that larger and better-controlled studies are warranted.

show abstract

PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients

Cited by 4 publications

References 28 publications

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a Potentially Novel Antiplatelet Drug which Antagonizes the Effect of Thromboxane A2

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a Potentially Novel Antiplatelet Drug which Antagonizes the Effect of Thromboxane A2

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Contact Info

Product

Resources

About